This makes it a potential target for ADCs (antibody–drug conjugates) in multiple myeloma treatment.[38] Our research has made a novel discovery, identifying the FCRL5 gene as a potential diagnostic biomarker for cancer diagnosis. This evidence concerns the gene FCRL5 and plasma cell myeloma.